Compared with anti-VEGF(R) monotherapy, the combination of anti-VEGF (bevacizumab) and VEGFR-TKI (anlotinib) therapies was associated with more severe hypertension, more rapid kidney injury, more extensive glomerular involvement (affecting >75% of glomeruli on average), and higher incidences of global mesangiolysis (100%) and diffuse basement membrane (GBM) double contours (75%) (Table 5). Here, VEGFA is linked to Hypertension.